Annonce • Apr 28
NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion. NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 7,150,000
Price\Range: KRW 3135
Transaction Features: Rights Offering New Risk • Apr 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩34b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩34b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.4b market cap, or US$28.8m). Annonce • Mar 12
NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026 NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea New Risk • Mar 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.2b market cap, or US$36.2m). New Risk • Jan 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩48.9b market cap, or US$33.1m). Reported Earnings • Nov 16
Third quarter 2025 earnings released: ₩91.85 loss per share (vs ₩226 loss in 3Q 2024) Third quarter 2025 results: ₩91.85 loss per share (improved from ₩226 loss in 3Q 2024). Revenue: ₩5.43b (up 162% from 3Q 2024). Net loss: ₩1.85b (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Annonce • Oct 24
NGeneBio Co., Ltd. announced that it has received KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. On October 23, 2025, NGeneBio Co., Ltd. closed the transaction, Annonce • Oct 17
NGeneBio Co., Ltd. announced that it expects to receive KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. NGeneBio Co., Ltd. announced a private placement to issue series 6 unregistered interest unsecured private convertible bonds for gross proceeds of KRW 25,000,000,000 on October 15, 2025. The transaction includes participation from new investors, Baro Savings Bank for KRW 11,000,000,000, Sangsangin Savings Bank for KRW 11,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 3,000,000,000. The bonds have coupon rate of 2% and yield to maturity of 6%. The bonds will mature on October 23, 2028. The bonds will be 100% converted into 14,671,361 common shares at a fixed conversion price of KRW 1,704 per share. The conversion period is from October 23, 2026 to September 23, 2028. The payment date of the transaction is October 23, 2025. The transaction has been approved by the board of directors of the company. The transaction is subject to prohibition of conversion and recommended split for one year from the date of issuance of debentures. Annonce • Jun 13
NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million. NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 533,616
Price\Range: KRW 1874
Transaction Features: Subsequent Direct Listing Annonce • Jun 07
NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million. NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 533,616
Price\Range: KRW 1874
Transaction Features: Subsequent Direct Listing Annonce • Jun 06
NGeneBio Co., Ltd. announced that it expects to receive KRW 999.996384 million in funding NGeneBio Co., Ltd. announced a private placement to issue 533,616 common shares at an issue price of KRW 1.874 for gross proceeds of KRW 999,996,384 on June 5, 2025. The transaction will include participation from new investors Farmers Alibaba Co. , Ltd 213,447 shares, Lee Deok-yong 213,447 shares, Oh wajong 53,361 shares and Hwang Yunseong shares. The transaction has been approved shareholders, restricted to a hold period, expected to close on June 13, 2025. Annonce • Jun 04
SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200). SH Healthcare Investment No. 1 Fund and others entered into an agreement to acquire 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) for KPW 2.2 billion on May 16, 2025. A cash consideration valued at KPW 1596.2 per share will be paid by SH Healthcare Investment No. 1 Fund. As part of consideration, an undisclosed value is paid towards common equity of NGeneBio Co., Ltd. After the transaction KT Corporation will completely exit from target and SH Healthcare Investment No. 1 Fund will hold 6.1% in target.
The expected completion of the transaction is June 2, 2025.
SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) on June 2, 2025. New Risk • Jun 02
New major risk - Revenue and earnings growth Earnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩6.9b revenue, or US$5.0m). Market cap is less than US$100m (₩39.9b market cap, or US$29.0m). New Risk • Apr 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩5.7b revenue, or US$3.9m). Market cap is less than US$100m (₩30.7b market cap, or US$20.9m). Annonce • Mar 07
NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025 NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea New Risk • Jan 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩34.5b market cap, or US$23.4m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$21.7m). New Risk • Dec 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Revenue is less than US$5m (₩6.2b revenue, or US$4.4m). Market cap is less than US$100m (₩35.4b market cap, or US$25.2m). Annonce • Apr 17
J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion. J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3.2 billion on April 3, 2024. The deal is expected to be completed on April 15, 2024.J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion on April 15, 2024. J&L Agent paid KRW 2.96 billion for acquisition of NGeneBio. New Risk • Apr 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 61% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.2m). Market cap is less than US$100m (₩79.9b market cap, or US$59.2m). New Risk • Sep 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 49% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Revenue is less than US$5m (₩5.9b revenue, or US$4.4m). Market cap is less than US$100m (₩75.2b market cap, or US$55.5m). Annonce • Sep 02
NGeneBio Co., Ltd. announced that it has received KRW 20 billion in funding On September 1, 2022, NGeneBio Co., Ltd. closed the transaction. 